Danno Pharmaceutical-B (06872): Formulation of the 2026 H share award plan

Zhitong Finance App News, Danuo Pharmaceutical-B (06872) issued an announcement to further establish and improve a long-term incentive mechanism, attract and retain outstanding talents, fully mobilize employees' enthusiasm and creativity, enhance employee cohesion and the company's core competitiveness, and thereby bring continuous growth return on investment to investors, effectively combine the interests of the company's shareholders, company interests, and personal interests of incentive recipients to promote the long-term, sustainable and healthy development of the company. The board of directors agreed to formulate an H share plan.

The H share plan uses the company's existing H share shares as an incentive share source to grant restricted shares to the incentive target. The company will act as a client and sign a trust agreement with the trustee to establish a trust to serve the H share plan based on the trust agreement. The trustee purchases the relevant H shares involved in completing the H share plan through market transactions on the premise of complying with the trust agreement and company instructions. The source of funds used to purchase reward shares is the company's own funds. The maximum number of bonus shares granted under the H share plan is 5% of the total number of shares of the company on the date the H share plan is adopted.